Throughout the meeting, Cole McLarty, Andy Henton, and Brad Gien will be at Booth 1426, engaging with attendees on how expert-driven execution across toxicology, pathology, regulatory strategy, and surgical model development can support decision-ready safety data.

Why Attend and Why We’ll be There: This year’s program reflects a field increasingly focused on how toxicology studies are designed and executed—not simply which endpoints are measured. Across sessions on new approach methodologies, PBPK-informed risk assessment, data integration, and reproducibility, a consistent theme emerges: interpretability and execution quality are central to regulatory confidence.

For us, ToxExpo provides an opportunity to engage directly with these challenges. Endpoint brings together expertise across toxicology study oversight, production-level surgical execution, pathology interpretation, and regulatory and risk assessment strategy. By embedding expert leadership early in study planning and maintaining continuity through execution and interpretation, we help reduce variability, align studies with regulatory intent, and support confident, decision-ready safety assessments.

By attending, we aim to:

• Advance Translational Alignment: Discuss how refined procedural and surgical execution, combined with toxicology and pathology oversight, supports mechanistic interpretation and improves the predictive value of safety studies.
• Strengthen Study Design and Reproducibility: Explore how integrated planning across toxicology, surgical, pathology, and regulatory teams improves consistency, transparency, and downstream usability of data.
• Support Regulatory Confidence: Engage in technical discussions around risk assessment, data integration, and evidence frameworks as expectations for scientific defensibility continue to rise.

We look forward to meeting you at SOT 2026! Visit Booth 1426 to connect with Cole, Andy, and Brad, or schedule a dedicated meeting.